FDA approves generic HIV shot for 120 low-income countries at $40 per year
The U.S. FDA has approved a generic version of the twice-yearly HIV-prevention injection lenacapavir, making it available at about $40 per person annually in 120 low- and middle-income countries.
KEY POINTS
- FDA approves generic lenacapavir, a twice-yearly HIV-prevention injection
- Generic version expected to cost $40 per person per year in 120 low- and middle-income countries
- Drug nearly eliminated new infections in two major clinical studies
- Brand-name Yeztugo costs $28,218 per year in the U.S. and remains patent-protected
- Generic developed by Dr. Reddy’s Laboratories under coordination by Unitaid, Clinton Health Access Initiative, and Wits RHI
The U.S. Food and Drug Administration has approved a generic version of lenacapavir, the world’s only twice-a-year injection to prevent HIV. The approval is intended to make the drug available more quickly and at a lower cost in 120 low- and middle-income countries.
The generic version is expected to cost about $40 per person per year in eligible countries, matching the price of currently available daily preventive pills. Because the injection is needed only twice a year, it is far more convenient than a daily pill regimen.
“With lenacapavir, we are much more hopeful.”
In two major clinical studies involving people at high risk of HIV, the drug nearly eliminated new infections. Health experts note that many people do not take daily medication consistently, and missing doses means they cannot be protected against HIV.
According to the World Health Organization, 41 million people worldwide were living with HIV, and 570,000 people died from HIV-related causes last year. Advocates estimate that 20 million people around the world need PrEP, the pre-exposure prophylaxis taken before potential exposure to the virus.
The brand-name version, Yeztugo, is made by Gilead Sciences and remains under patent protection in the United States. Its U.S. list price before insurance is $28,218 per year, and generic lenacapavir cannot be sold in the U.S. while that patent stands.
The generic was developed by India’s Dr. Reddy’s Laboratories under an agreement coordinated by Unitaid, the Clinton Health Access Initiative, and the Wits RHI medical research institute. The FDA approved it under a longstanding practice designed to ensure the quality of HIV medications.
Carmen Pérez Casas, HIV lead for Unitaid, said people do not always take their daily dose, and without it they cannot be protected. Carolyn Amole, who leads the HIV program for the Clinton Health Access Initiative, said scaling access to 20 million people could actually help bring an end to the HIV epidemic.
3 more sources below
COMMENTS (0)
No comments yet. Be the first.
RELATED STORIES
Cristina Kirchner Opens Door to 2027 Presidential Bid if Rights Restored
The former Argentine president said she could run again in 2027 if she recovers her political rights, following a Washington Post interview.
Brazilian court lifts secrecy on Tancredo Neves medical records after 41 years
Family of the elected president seeks answers on suspected medical errors surrounding his 1985 death.
Latino voter discontent in South Texas could help Democrats in November midterms
Economic hardship and immigration raids are eroding Republican support in a region Trump won in 2024.
- Belgian federal budget talks collapse as coalition parties clash over taxes and spending
- Metal needles found in Halloween sweets across Germany
- Trump administration pledges $15 billion to U.S. farmers ahead of midterms
- Health Minister Opens Akçakoca Hospital and Launches Home Health Coordination Center
- Cyberattack Hits Supermarket Freezers in Sweden and Belgium
This page was compiled with AI assistance from the outlets named above and passed an automated language check before publication. Montegre has no reporters of its own; the byline names the outlets the story was compiled from. Method and editorial standards